NCT01328171已完成2 期
An Open-label 2:1 Randomized Phase II Study of Panitumumab Plus FOLFOXIRI or FOLFOXIRI Alone as First-line Treatment of Patients With Non-resectable Metastatic Colorectal Cancer and RAS Wild Type
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 93
- 试验地点
- 19
- 主要终点
- overall response rate
研究概览
简要总结
The aim of the trial is to optimize response rates and rates of secondary resections of metastases in patients with initially non-resectable metastatic colorectal cancer of RAS wildtype. The patients will be treated in two therapy groups:
Experimental arm A: Chemotherapy with FOLFOXIRI + panitumumab Standard arm B: Chemotherapy with FOLFOXIRI
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Cohort I: Histologically confirmed and definitively inoperable or irresectable metastatic colorectal cancer. Focus on patients with large tumor load at metastatic sites and/or symptomatic metastatic disease
- •Cohort II: Chance of secondary resection with curative intent defined and reviewed by expert panel
- •Adult patients (≥ 18 years of age)
- •RAS wild-type tested in
- •KRAS exon 2 (codons 12/13)
- •KRAS exon 3 (codons 59/61)
- •KRAS exon 4 (codons 117/146)
- •NRAS exon 2 (codons 12/13)
- •NRAS exon 3 (codons 59/61)
- •NRAS exon 4 (codons 117/146) assessed by an institution participating in and certified by the specific working group of the Deutsche Gesellschaft für Pathologie)
- •At least one measurable lesion according to RECIST measured within 3 weeks prior to registration
- •No previous chemotherapy for metastatic disease (adjuvant chemotherapy for non-metastatic disease is allowed if terminated more than 6 months ago)
- •Performance status ECOG 0-1
- •Male and female subjects > 18 years of age
- •Adequate haematological, hepatic, renal and metabolic function parameters:
- •Leukocytes > 3000/mm³, ANC ≥ 1500/mm3, platelets ≥ 100,000/mm3, Hb > 9g/dl (may be transfused or treated with erythropoietin to maintain or exceed this level)Creatinine clearance ≥ 50 ml/min or serum creatinine ≤ 1.5 x upper limit of normal Bilirubin ≤ 1.5 x upper limit of normal, GOT-GPT ≤ 2.5 x upper limit of normal in absence of liver metastases, or ≤ 5 x upper limit of normal in presence of liver metastases, AP ≤ 5 x upper limit of normal Magnesium ≥ lower limit of normal; calcium ≥ lower limit of normal (may be substituted to maintain or exceed this level)
- •Negative pregnancy test and willingness to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment (adequate: oral contraceptives, intrauterine device or barrier method in conjunction with spermicidal jelly).
- •Before subject registration, written informed consent must be given according to ICH-GCP, and national/local regulations.
排除标准
- •Past or current history of malignancies except for the indication under this study and curatively treated:
- •Basal and squamous cell carcinoma of the skin
- •In-situ carcinoma of the cervix
- •Other malignant disease without recurrence after at least 5 years of follow-up
- •Clinically significant cardiovascular disease in (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 6 months before enrolment.
- •Clinically relevant interstitial lung disease, e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan.
- •History of evidence upon physical examination of CNS disease unless adequately treated (e.g. primary brain tumour, seizure not controlled with standard medical therapy, brain metastases or history of stroke).
- •Pre-existing neuropathy > grade 1 (NCI CTCAE), except for loss of tendon reflex
- •Allogeneic transplantation requiring immunosuppressive therapy.
- •Severe non-healing wounds, ulcers or bone fractions.
- •Evidence of bleeding diathesis or coagulopathy.
- •Patients not receiving therapeutic anticoagulation must have an INR < 1,5 ULN and aPTT < 1,5 ULN within 7 days prior to randomization. The use of full dose anticoagulants is allowed as long as the INR or aPTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least two weeks at the time of randomisation.
- •Concomitant therapy with certain anti-viral medicines (sorivudine and brivudine or analogue compounds).
- •Major surgical procedure, open biopsy, nor significant traumatic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the course of the study except for surgery for colorectal cancer with curative intent and central venous line placement for chemotherapy administration.
- •Pregnancy or breastfeeding women.
- •Subjects with known allergy to the study drugs or to any of its excipients.
- •Known DPD deficiency.
- •Current or recent (within the 28 days prior to starting study treatment) treatment of another investigational drug or participation in another investigational study.
- •Known grade III/IV allergic reaction against monoclonal antibodies.
- •Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the subject before registration in the trial.
研究组 & 干预措施
A (FOLFOXIRI + Panitumumab)
Experimental
FOLFOXIRI + Panitumumab
干预措施: FOLFOXIRI + Panitumumab (Drug)
B (FOLFOXIRI)
Active Comparator
FOLFOXIRI
干预措施: FOLFOXIRI (Drug)
结局指标
主要结局
overall response rate
时间窗: up to about 6 month
RECIST
次要结局
- disease control rate(up to about 6 month)
- overall survival(From date of randomization until the date of death from any cause assessed up to 4 years)
- liver toxicity for resected patients (central histological review); biopsies should be obtained for all patients pre-treatment(up to 1 year)
- QL (QLQ C30)(Pre-treatment, before start of every 3rd cycle and at the end of treatment)
- translational research (EGFR genetics and proteomics): prognostic and predictive impact on efficacy outcomes(up to 4 years)
- progression free survival(From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 years)
- overall response rate in each cohort(up to about 6 month)
- duration of response(From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 years)
- time to recurrence (cohort II in case of secondary resection)(up to 4 years)
- toxicity and feasibility(up to about 6 month)
- secondary resection rate with curative intent for patients cohort I(up to about 6 month)
- pathological response in liver surgery specimen(up to about 6 month)
- time to response(up to about 6 month)
研究者
研究点 (19)
Loading locations...
相似试验
已完成
2 期
Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic MetastasesColorectal CancerNCT01442935UNICANCER256
进行中（未招募）
2 期
A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCCHead and Neck Squamous Cell CarcinomaNCT05054439Sichuan Baili Pharmaceutical Co., Ltd.45
终止
2 期
Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast CancerTriple Negative Breast CancerNCT02984683Sanofi23
已完成
1 期
Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic CancerMetastatic Colorectal CancerMetastatic Pancreatic CancerNCT03168139TME Pharma AG20
招募中
不适用
Radiotherapy or Observation of Liver Metastases in Small Cell Lung CancerComplications RadiotherapyNCT05150145Guizhou Medical University66